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Successful Reversal of
Furosemide-Induced Secondary
Hyperparathyroidism With Cinacalcet
Tarak Srivastava, MD,a Shahryar Jafri,a William E. Truog, MD,b Judith Sebestyen
VanSickle, MD,a Winston M. Manimtim, MD,b Uri S. Alon, MDa

Secondary hyperparathyroidism (SHPT) is a rare complication of
furosemide therapy that can occur in patients treated with the loop diuretic
for a long period of time. We report a 6-month-old 28-weeks premature
infant treated chronically with furosemide for his bronchopulmonary
dysplasia, who developed hypocalcemia and severe SHPT, adversely
affecting his bones. Discontinuation of the loop diuretic and the addition
of supplemental calcium and calcitriol only partially reversed the SHPT,
bringing serum parathyroid hormone level down from 553 to 238 pg/mL.
After introduction of the calcimimetic Cinacalcet, we observed a sustained
normalization of parathyroid hormone concentration at 27 to 63 pg/mL
and, with that correction, of all biochemical abnormalities and healing of the
bone disease. No adverse effects were noted. We conclude that in cases of
SHPT due to furosemide in which traditional treatment fails, there may be
room to consider the addition of a calcimimetic agent.
Furosemide therapy in the
neonatal/infantile period is well
known to be associated with
medullary nephrocalcinosis from
hypercalciuria caused by the
loop diuretic.1,2 A less known
complication of chronic treatment
with furosemide is the development
of secondary hyperparathyroidism
(SHPT).3– 6 The latter is attributed
to the hypercalciuria, leading to the
development of hypocalcemia, which
stimulates parathyroid hormone (PTH)
secretion,6,7 but recent literature
also suggests an additional, direct
stimulating effect of furosemide on the
parathyroid glands.8 It is expected that
discontinuation of the loop diuretic, at
times combined with supplementation
with calcium and active vitamin
D metabolites, will reverse the
SHPT. However, if the parathyroid
glands achieve a significant level of
hyperplasia, the task of controlling
SHPT will be difficult, and the

endocrinopathy may persist for a
prolonged period.

In recent years, a calcimimetic agent,
Cinacalcet, which acts on the calciumsensing receptor has become available
to suppress PTH.9 The calcimimetic
agent changes the configuration of
the calcium-sensing receptor in the
parathyroid glands, making them more
sensitive to circulating serum calcium,
resulting in decreased secretion of
PTH. Although originally created
for use in adults with SHPT, there
have been now several reports of
successful use of this agent in children
with SHPT from various genetic and
acquired etiologies.10–13
 We report
our novel experience in a premature
infant with severe bronchopulmonary
dysplasia (BPD) necessitating longterm treatment with furosemide who
developed SHPT. After observing only
partial response to traditional therapy
with calcium and calcitriol, the SHPT
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Case Report

was successfully reversed with
Cinacalcet.

Case Report
The child was born at 28 weeks’
gestation with a birth weight of
830 g. He was transferred from his
birth hospital at 2 months of age
for ongoing needs of prematurity,
severe BPD, and possible need for
tracheostomy. On admission to our
institution, furosemide was added
to his ongoing thiazide therapy
to treat his respiratory condition.
At age 5.5 months, he underwent
tracheostomy and placement of
ventriculoperitoneal shunt for
hydrocephalus. MRI of the brain
performed for evaluation of the
ventriculoperitoneal shunt showed
severe demineralization of the
bones (Fig 1). The skeletal survey
conducted the next day showed
abnormal bony demineralization
concerning for a metabolic bone
disorder. That day serum ionized
calcium (iCa) was 0.99 mmol/L
(normal 1.13–1.37), and he was
started on calcium supplementation.
Further detailed evaluation in the
coming days (Table 1, week −7.0),
when his chronological age was 6
months and weight 6.3 kg, detected
decreased serum calcium (8.9 mg/dL);
iCa 1.09 mmol/L; elevated PTH
(553 pg/mL), alkaline phosphatase
(ALP; 420 U/L), and 1,25(OH)2vitamin D (689 pg/mL); and normal
phosphorus (5.4 mg/dL), 25(OH)vitamin D (65 ng/mL), and urine
calcium/creatinine ratio (0.22 mg/mg).
At that time, his treatment of BPD
included furosemide (3 mg/kg/day),
chlorothiazide (22.5 mg/kg/day),
and prednisone (0.5 mg/kg every
48 hours). Renal ultrasound showed
no medullary nephrocalcinosis.
His nutritional formula provided
elemental calcium, phosphorus,
and vitamin D of 603 mg/day,
437 mg/day, and 260 U/day,
respectively. Genetic mutation
analysis for conditions associated
2

with inherited forms of rickets
and/or osteopetrosis (namely VDR,
CASR, PHEX, CYP27B1, CYP2R1,
DMP1, CLCN7, SOST, LRP4, SNX10,
TMFSF11, TNFRSF11A, and OSTM1)
were negative. A microarray did not
identify any deletion or duplication.
Calcitriol was added to address
his hypocalcemia. Over the next 3
weeks, his serum PTH decreased but
remained elevated at 257 pg/mL
(Table 1, week −3.4). At this point,
our team was consulted, and the
diagnosis of furosemide-induced
SHPT was made. Furosemide was
discontinued and the chlorothiazide
dose doubled. In coming weeks, a
further decrease in PTH levels was
noted, but the dose of calcitriol and
calcium supplementation had to be
decreased to avoid hypercalcemia.
Nevertheless, despite sustained
normalization of serum calcium over
this 6-week period, his serum PTH
remained elevated (Table 1, week 0).
After discussion with the family, a
decision was made to initiate oral
Cinacalcet 3 mg/day (0.4 mg/kg/day)
in 2 divided doses. Over the next
2 weeks (Table 1: Cinacalcet Course A),
PTH normalized at 15 to 25 pg/mL.
Due to hypocalcemia, calcium
supplementation was increased.
With serum PTH and calcium levels
within their normal range, Cinacalcet
was subsequently discontinued
(Table 1, week 2.0). Within the
next 2 weeks, the serum PTH
rebounded to 151 to 234 pg/mL.
This suggested significant
hyperplasia of the parathyroid glands
requiring sustained pharmacological
suppression of PTH. An attempt
to image the parathyroid glands
by using neck ultrasound failed
because of neck size and presence
of tracheostomy. At this point,
Cinacalcet was reinitiated (Table 1:
Cinacalcet Course B) with
concomitant calcitriol and calcium
supplementation. Serum PTH
eventually normalized and stayed
within the normal range for the next
12 weeks. Calcitriol was discontinued
first, calcium supplementation was

tapered and discontinued next, and
finally Cinacalcet was stopped (Table 1,
weeks 11.5–16.5). The child was
then able to maintain serum calcium
and PTH levels in their normal
ranges until discharge 8 weeks later.
At follow-up a month later, serum
calcium and PTH were normal at
10.2 mg/dL and 78 pg/mL, respectively.
The child tolerated therapy with
Cinacalcet without any adverse
effects. Throughout this course,
his serum creatinine and urine
calcium/creatinine ratio remained
normal. The renal ultrasound
on last follow-up showed no
nephrocalcinosis. Serum ALP, which
was originally elevated, gradually
normalized. Follow-up radiographs
done at 1 year of age showed normal
mineralization with resolution of
metaphyseal cupping and fraying
(Fig 1).

Discussion
Furosemide is a potent loop diuretic
with action in the loop of Henle that
results in decreased sodium and
water reabsorption; it is often used
in infants with BPD.14 However,
its action also results in decreased
calcium reabsorption because
calcium and sodium reabsorption are
coupled at this site.15 The increased
urinary calcium excretion may
result in formation of medullary
nephrocalcinosis or stones.1,2 In
older patients, furosemide has also
been reported to be associated with
decreased bone mineral density,
osteoporosis, and high risk for
fractures.16– 18
 In addition, there have
been reports about the association of
the loop diuretic with development
of SHPT.3– 8 Coe et al5 in 1973
demonstrated that adults treated
with furosemide had elevated PTH
similar to adults with persistent
hypercalciuria. In 1985, Fujita et al6
showed that adults treated for a
week with oral furosemide had
elevated urine calcium (effect on
loop of Henle) and cyclic adenosine
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range (Table 1: Cinacalcet Course
A). After Cinacalcet was stopped,
PTH levels immediately rebounded
and were brought back to normal
with the reintroduction of the
calcimimetic. We believe that the
hormonal rebound provides a proof
of concept that the suppression of
PTH was the result of treatment with
Cinacalcet and not coincidental.

FIGURE 1

MRI (left panel) at 6 months of age showing massive expansion of the calvarial vault suggestive
of metabolic bone disease. Radiograph of the right wrist (right upper panel) performed the next
day showing diffuse demineralization with widening and flaring of the metaphysis. The follow-up
radiograph (right lower panel) done at 1 year of age, 4 months after initiation of Cinacalcet therapy,
shows normalization of bone mineralization and metaphyseal anatomy.

monophosphate excretion (effect
of elevated PTH). More recently,
cross-sectional analyses of large data
sets from the United States, Brazil,
and Australia have shown the loop
diuretic to be associated with SHPT
in adults with both normal and
reduced renal function.4,7,
 19
 –21

Similarly, Venkataraman et al3
communicated this complication
in 1983 in 4 preterm infants
who consequently developed
hyperparathyroid bone disease, but
no additional pediatric cases have
since been reported. Although SHPT
from furosemide has been reported
in adults, it seems to be a rarity in the
pediatric population.
The mechanism of furosemideinduced SHPT has been
conventionally attributed to
increased urinary calcium excretion,
but that alone does not completely
explain the development of
SHPT from calciuria. Riss et al22
showed that although thiazides
decrease urine calcium excretion
in primary hyperparathyroidism,
they do not affect serum PTH
level. Similarly, our case had SHPT

despite normal urine calcium
excretion, which could be explained
by adjunctive thiazide therapy
or a calcium-depleted skeleton.
Another possible mechanism for
the development of SHPT is based
on the new observation of a direct
stimulatory effect of furosemide on
the parathyroid cells acting via the
NKCC1 receptor.8

In the present case, the infant,
with ventilator-dependent BPD,
was treated with furosemide for
4 months, when the brain MRI
followed by skeletal radiographs
showed severe osteopenia (Fig
1). The biochemical evaluation
that followed was consistent with
furosemide-induced SHPT (Table
1). After calcitriol and calcium
supplementation decreased PTH
only partially, furosemide was
discontinued. Over the next 3 weeks,
serum PTH further decreased but
remained elevated. It was realized
that further suppression of PTH
secretion may come at the cost
of hypercalcemia. Cinacalcet was
therefore added, and subsequently
PTH was decreased to its normal

Coe et al5 reported that SHPT
associated with persistent
hypercalciuria was secondary
to hyperplasia of the glands and
would respond to calcium infusion.
Venkataraman et al3 reported that
autopsy in one of the premature
infants who developed furosemideinduced SHPT showed enlarged
parathyroid glands. Our attempt to
image the parathyroid glands was
not successful due to presence of
tracheostomy. However, on the basis
of the course of events, we believe
that also in our case, the parathyroid
glands achieved a significant level
of hyperplasia making the task of
controlling SHPT more difficult;
specifically, if left to conventional
treatment, the state of SHPT would
have persisted for a prolonged
period. Cinacalcet, a calcimimetic
that acts on the calcium-sensing
receptor to suppress PTH secretion,
was previously shown to be effective
and safe in reversing various types
of primary and SHPT in both adults
and children.10– 13
 Furthermore, as
recently shown by Muller et al,8
it negates the direct effect of
furosemide on the parathyroid
glands. It thus seems to be the
ideal drug to use in a circumstance
such as in our patient for rapid
and safe correction of SHPT. As
with our previous experience with
vitamin D–resistant rickets and
pseudohypoparathyroidism type 1b,
and as was the case in our current
patient, bringing serum PTH back
into the normal range resulted in
normalization of serum ALP and
healing of the bone disease.10,11

As previously observed in animals
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TABLE 1 Effect of Therapy With Elemental Calcium, Calcitriol, and Cinacalcet Before and On and Off Cinacalcet on Serum Biochemical Variables in a
Premature Infant With Furosemide-Induced SHPT
Time, wk
Reference range
Pre-cinacalcet
−7.0
−6.1
−5.0
−3.4a
−2.6
−1.4b
0.0
Cinacalcet course A
0.6
1.0
1.6
2.0c
Off cinacalcet
2.6
3.6
Cinacalcet course B
4.6
6.6d
8.0
9.0
10.5
11.5
12.5
13.5
14.5
15.5
16.5
Off cinacalcet
18.0
20.5
24.5

Elemental
Calcium, mg/d

Calcitriol, µg/d

Cinacalcet, mg/d

iCa, mmol/L

Serum P, mg/dL

Serum PTH,
pg/mL

Serum ALP, U/L

—

—

—

1.13–1.37

4.2–7.0

10–89

110–320

560
560
560
560
560
280
280

0.15
0.30
0.30
0.30
0.15
0.15

—
—
—
—
—
—
—

1.09
1.21
1.13
1.26
1.43
1.27
1.30

5.4
4.9
5.4
6.6
6.3
5.9
5.6

553
531
484
257
161
157
238

420
419
553
—
—
336
335

280
280
280
600

0.15
0.15
0.15
0.15

6.9
7.8
6.0
6.0

1.17
1.33
1.01
1.12

5.4
5.7
6.0
6.0

137
25
15
25

—
—
—
—

600
600

0.15
0.15

—
—

1.27
1.31

6.2
5.9

234
151

—
—

600
780
780
780
780
780
780
780
760
240
—

0.15
0.15
0.15
0.15
0.15
0.15
—
—
—
—
—

3.5
7.2
6.9
6.6
3.3
3.3
5.4
4.8
4.8
4.8
2.4

1.26
1.21
1.19
1.17
1.31
1.34
1.29
1.19
1.23
1.27
1.28

5.1
7.6
7.1
7.6
5.9
8.7
5.7
8.2
7.2
6.9
7.6

117
119
10
90
63
92
104
27
44
28
55

216
—
—
—
—
—
—
—
—
—
—

—
—
—

—
—
—

—
—
—

1.38
1.32
1.37

7.3
5.8
5.9

63
35
45

190
—
—

Serum creatinine ranged between 0.22 and 0.29 mg/dL throughout the study period (reference range 0.06–0.45 mg/dL).
a Furosemide was discontinued and dose of chlorothiazide doubled.
b Calcium and calcitriol supplementation were decreased due to hypercalcemia (iCa 1.43 at week −2.6).
c Calcium supplementation was increased due to hypocalcemia (iCa 1.01 at week 1.6).
d Calcium supplementation was increased due to hypocalcemia (iCa 1.06 at week 6).

and humans, Cinacalcet’s main
adverse effect was the development
of hypocalcemia, requiring the
adjustment of supplemental active
vitamin D metabolite to sustain
serum iCa concentration within its
normal range.10,11,
 23


Several lessons can be learned
from the present case. In children
chronically treated with a loop
diuretic, close attention should be
paid to their mineral metabolism,
specifically periodic assessment
of serum iCa and PTH levels and
urine calcium should be performed.
Once abnormalities are detected, all
efforts should be made to discontinue
4

the loop diuretic, and if diuresis is
still required, the use of a thiazide
diuretic is preferable. In case this
maneuver does not help reverse
SHPT, calcium and active vitamin
D metabolites need to be added. If
satisfactory suppression of PTH is
still not noted, we now have in our
armamentarium the calcimimetic
agent. We recommend, on the basis
of others’ and our own experience,
continuing to monitor serum iCa
and urine calcium closely because
some patients under calcimimetic
treatment develop hypocalcemia
responding to calcitriol and/
or hypercalciuria responding to
thiazides.
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